Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

JunB is a gatekeeper for B-lymphoid leukemia.

R G Ott1, O Simma, K Kollmann

  • 1Institute of Pharmacology, Medical University of Vienna (MUW), Vienna, Austria.

Oncogene
|February 14, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Peripheral blood DNA methylation profile and immune checkpoint inhibitor response in cancer patients.

ESMO open·2026
Same author

Predictive potential of patient-specific immunological characteristics in solid cancers: circulating monocytes, myeloid-derived suppressor cells, T cells, and the T-cell receptor repertoire.

ESMO open·2026
Same author

Identifying the genomic landscape of EGFR-mutant lung cancers with central nervous system metastases.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

International comparisons and holistic patient care.

BJOG : an international journal of obstetrics and gynaecology·2021
Same author

Core-binding factor leukemia hijacks the T-cell-prone PU.1 antisense promoter.

Blood·2021
Same journal

SRD5A3-mediated aberrant N-glycosylation of SCARA5 promotes ferroptosis in lung adenocarcinoma.

Oncogene·2026
Same journal

Aberrant splicing in human cancer shows possible functional impact on transcription factors.

Oncogene·2026
Same journal

The crosstalk between RNA m6A modification and protein lactylation: emerging insights into tumor progression.

Oncogene·2026
Same journal

Correction: Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway.

Oncogene·2026
Same journal

Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer.

Oncogene·2026
Same journal

Histone lactylation-driven IGF2BP3 promotes intrahepatic cholangiocarcinoma progression via SPP1/CD44-dependent macrophage polarization.

Oncogene·2026
See all related articles

JunB loss accelerates leukemia progression by enabling transformed cells to proliferate faster. This irreversible reprogramming, linked to altered cell cycle regulators, results in more aggressive B-lymphoid leukemia.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Loss of JunB is observed in human leukemia and lymphoma.
  • The role of JunB in disease progression remains unclear.

Purpose of the Study:

  • To investigate the consequences of JunB deficiency in Abelson-induced B-lymphoid leukemia.
  • To determine if JunB loss contributes to leukemia progression and malignancy.

Main Methods:

  • Utilized a mouse model of Abelson-induced B-lymphoid leukemia with JunB deficiency (junB(Delta/Delta)).
  • Assessed leukemia incidence, latency, and phenotype in JunB-deficient and control groups.
  • Analyzed proliferation rates, cell cycle kinase (cdk6), and inhibitor (p16(INK4a)) expression in transformed cells.
  • Investigated the role of promoter methylation in epigenetic reprogramming.

Related Experiment Videos

Main Results:

  • JunB-deficient mice showed increased incidence and reduced latency of Abelson-induced leukemia.
  • JunB-deficient leukemic cells exhibited faster proliferation and a more malignant phenotype.
  • Accelerated proliferation was associated with increased cdk6 and decreased p16(INK4a) levels.
  • The enhanced proliferation was irreversible and linked to p16 promoter methylation.

Conclusions:

  • JunB acts as a gatekeeper in tumor evolution, preventing malignant progression.
  • Loss of JunB leads to irreversible cellular reprogramming, enhancing leukemic cell proliferation.
  • JunB deficiency contributes to the development of more aggressive B-lymphoid leukemia.